Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Nov 9.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3334–3348. doi: 10.1158/1055-9965.EPI-09-0429

Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example

Richard J O’Connor 1, K Michael Cummings 1, Vaughan W Rees 2, Gregory N Connolly 2, Kaila J Norton 1, David Sweanor 3, Mark Parascandola 4, Dorothy K Hatsukami 5, Peter G Shields 6
PMCID: PMC4637821  NIHMSID: NIHMS728143  PMID: 19959680

Abstract

Tobacco products are widely sold and marketed, yet integrated data systems for identifying, tracking, and characterizing products are lacking. Tobacco manufacturers recently have developed potential reduction exposure products (PREPs) with implied or explicit health claims. Currently, a systematic approach for identifying, defining, and evaluating PREPs sold at the local, state or national levels in the US has not been developed. Identifying, characterizing, and monitoring new tobacco products could be greatly enhanced with a responsive surveillance system. This paper critically reviews available surveillance data sources for identifying and tracking tobacco products, including PREPs, evaluating strengths and weaknesses of potential data sources in light of their reliability and validity. Absent regulations mandating disclosure of product-specific information, it is likely that public health officials will need to rely on a variety of imperfect data sources to help identify, characterize, and monitor tobacco products, including PREPs.

Keywords: Tobacco, Surveillance, Monitoring, Public Health

Introduction

Surveillance is “[c]ontinuous analysis, interpretation, and feedback of systematically collected data, generally using methods distinguished by their practicality, uniformity, and rapidity rather than by accuracy or completeness.”(1) In tobacco control, surveillance efforts traditionally have focused on the prevalence of smoking, quitting rates, and numbers of cigarettes smoked.(24) The tobacco control community in the United States has placed less emphasis on surveillance of tobacco products themselves, with the possible exception of brand share or preference.(511) Indeed, tar and nicotine emissions, the traditional method of product surveillance, is regarded by the public health community as an inadequate and misleading way to characterize products.(1216) The dearth of objective data about products creates challenges for ongoing tobacco control efforts. The lack of adequate product surveillance was manifested most dramatically in the late 1970s and 1980s, when systematic testing of tar and nicotine emissions was conducted without adequate scientific understanding of the role of cigarette design and smoking behavior on measurements.(15)

Potential Reduced Exposure Products

In the 1990s, tobacco manufacturers began introducing new and modified tobacco products with explicit or implicit claims of health benefits compared to regular cigarettes.(17;18) Among these have been cigarette-like products such as Accord, Premier, and Eclipse (which purportedly heat rather than burn tobacco), modified cigarettes such as Quest, Advance, Omni, and Marlboro Ultrasmooth, and smokeless tobacco products such as Ariva and Revel. A 2001 Institute of Medicine (IOM) report(17) concluded that while data suggest that reducing risk of disease by reducing tobacco toxicant exposure is feasible, no current products have been sufficiently evaluated to demonstrate risk reduction. The IOM developed the acronym “Potential Reduced Exposure Products” (PREPs) to describe the class of products, and proposed a research agenda to investigate their exposure- and harm-reduction potential. They also noted the potential for PREPs to have adverse effects, both at the individual and population level, by delaying quitting or fostering the resumption of tobacco use among former smokers. Additionally, the tobacco control community has cautioned that claims made about PREPs need to be evaluated by valid, independent data and studied under their actual conditions of use in order to ensure the data are relevant to actual human exposure and risk. (1922) There is, thus, a substantial need for accurate and timely data that reveals when, where, how, and what types of products have been introduced, as well as how the products are being used.

PREP surveillance in the context of the larger tobacco market

To perform surveillance on PREPs, however, one must look to the larger product market, in order to distinguish those products that might reasonably be expected to reduce exposures, or be perceived by consumers to do so, from those that do not. Recall that PREP is a term coined by the Institute of Medicine committee, used more by scientists than in product marketing. So, PREPs may not be self-identified. This is further complicated by the fact that even product characteristics may not be explicitly stated by the manufacturer, and exposure reduction messages may be communicated through indirect means.

There are imposing obstacles to achieving a reliable and valid surveillance system for tobacco products. Although the US market is dominated by a few major manufacturers (e.g., Philip Morris, Reynolds-American, U.S. Smokeless Tobacco, and Lorillard) and “super brands” (e.g., Marlboro, Newport, Camel, Copenhagen, and Skoal), the overall market is quite fractured. The 2000 Federal Trade Commission (FTC) report on tar, nicotine, and carbon monoxide yields lists 1268 separate cigarette brand or sub-brand products.(23) The most recent NY State fire standards compliance list contains 1381 tobacco brand or sub-brands.(24) Added to this variation in cigarettes are product classes such as hand-rolled cigarettes, cigarette-like devices (e.g., Eclipse, Premier, Accord), smokeless tobacco (chewing tobacco, dry snuff, moist snuff), pipe tobacco, and large and small cigars, many of which have gained market share over the past several years. (2527)

Tobacco companies may introduce only one or two new distinct brands in a given year, if any. Brands comprise the product itself (e.g., features, design, and quality), accompanying marketing, and use by consumers such that “…over time a brand develops a series of attachments and association that exist over and beyond the objective product.” (28) However, the introduction of new styles or variants of an existing brand, called extensions, is common. Brand extensions are a heavily investigated area of marketing science—basically, for an extension to be successful, consumers must see the extension as sensible, and key brand associations are competence and image.(2830) As Polly and Dewhirst note: “Merit, as a free-standing brand, had difficulties in being perceived as flavourful, whereas in contrast, product line extensions like Marlboro Lights had the advantage of being perceived as more flavourful due to the taste reputation of the "parent" brand.”(31) So, significance attaches to whether a new product bears the name of an existing brand, or becomes its own brand. Table 1 shows a list of new tobacco products and line extensions introduced to the US market in 2007 through Winter 2008 (the time this paper was drafted). In the last year, most ‘new’ products introduced have been extensions of existing product lines, in some cases into new classes of product (e.g., using the Marlboro name for smokeless tobacco). Manufacturers may also modify existing brands in various ways, often without informing the public about changes to the brand. For example, a report analyzing Massachusetts mandated disclosure data showed that nicotine levels of cigarettes had, on average, increased nearly 15% across the 1997–2005 period.(32) Tobacco documents also describe the reengineering of Camel to match advertising claims regarding smoothness, in order to increase appeal to youth.(33) However, only a fraction of new products might be considered PREPs based on claims or design. Thus, PREPs are one element in a broader scheme of product innovation, which tobacco manufacturers can use to seek marketplace advantages over competitors. However, PREPs do present unique challenges to surveillance efforts because of the diversity of PREP products, their novel characteristics and use of innovative design features, and the potential of the marketing of these products to impact smoking-related behaviors.

Table 1.

New tobacco products introduced by major manufacturers in the US, 2007–2008

Company Product LE NPC Description

Philip Morris USA Marlboro Smooth X Cigarette (menthol)
Marlboro Virginia Blend X Cigarette (single leaf blend)
Marlboro Snus X X Smokeless pouches
Marlboro Moist Snuff X X Loose moist snuff
Marlboro Ultralight 72s X Cigarette (72mm length)

Reynolds-American Camel No.9 X Cigarette
Kool XL X Cigarette
Kool Flow X Cigarette
Kool Groove X Cigarette
Camel Signature Blends X Cigarette (flavored)
Camel Crush X Cigarette (crushable menthol filter pellet)

Lorillard Newport M Blend X Cigarette
Triumph Snus X Smokeless pouches

Liggett/Vector Grand Prix Snus X Smokeless pouches
Tourney Snus X Smokeless pouches

Swedish Match Red Man Moist Snuff X X Loose moist snuff
Triumph Snus X Smokeless pouches

UST Cope X Loose moist snuff

LE = line extension; NPC = New brand or product class

Tobacco product reporting requirements in the US

U.S. Federal regulations regarding tobacco products currently lack central coordination. The FTC receives reports of industry marketing expenditures and has traditionally set standards for machine testing of tar and nicotine content for smoked tobacco products and received yearly reports of such data (public reports ceased in 2000). The Centers for Disease Control and Prevention (CDC) receives annual lists of additives used in manufacture from cigarette and smokeless tobacco manufacturers; smokeless manufacturers are also required to report nicotine and related product details (total and un-ionized nicotine, moisture content, and pH). The Alcohol and Tobacco Tax and Trade Bureau (TTB) of the Department of the Treasury is responsible for the licensure of tobacco product manufacturers, importers, and exporters for taxation purposes. There is current pending legislation in Congress that would place many of these functions, as well as additional requirements, under the purview of the Food and Drug Administration (FDA). Several states also have separate regulations governing tobacco products. For example, Massachusetts and Texas require product disclosures for nicotine yield on brands commanding at least 1.5% market share. Under a comprehensive regulatory system, surveillance could be conducted by federal regulatory agencies; however, this paper addresses currently available sources of information that could serve surveillance purposes in the absence of such regulation.

Clearly, a surveillance system for PREP-like tobacco products needs to be developed, whether inside a regulatory framework (e.g., federal legislation, state health departments) or outside of regulation via partnerships between scientists and tobacco control advocates.(19;3440) The purpose of this paper is to critically examine existing methods for identifying and characterizing new and modified products in the tobacco marketplace that may be of interest to public health officials. This is not intended to be a review of product innovations as such, nor a review of surveillance systems of health effects and outcomes associated with tobacco products. Rather, we intend to describe of how scientists and regulators could systematically identify and track PREPs in the context of the larger set of ‘new’ or modified products. Our intended target audience is public health officials, to increase their urgency for moving forward with tobacco product surveillance activities in their respective jurisdictions.

We classify the methods identified by three phases of product surveillance: 1) Identifying a PREP that has been or is about to be released; 2) Characterizing that product in terms of claims, design, and other features; 3) Monitoring the sales, trial, and adoption of the product. These phases were chosen to be inclusive of a wide range of available information that could give a broad picture of a PREP in the context of other tobacco products, both pre- and post-market.

Methods

In order to identify literature pertaining to tobacco product surveillance, a systematic search of PubMed was performed. Search terms included the following in various combinations: cigarette, tobacco, product, surveillance, monitoring, tracking, and marketing. To be included in this review, a paper had to substantively address at least one of three areas of product surveillance (identification, characterization, monitoring). Papers dealing solely with surveillance of health effects of tobacco products or patterns of use (i.e., youth smoking) were excluded. Subsequent to the PubMed search, we examined other potential methods for identifying new and modified products in Tobacco Documents Online1, and by using databases such as PsycINFO, Business Source Complete, Hoovers, and Google. Search terms included: new product development, competitor analysis, SWOT analysis, product launch, market research, consumer psychology, and branding (in the context of tobacco products). Article citation lists were checked to locate any relevant papers not identified by the keyword searches.

The papers related to tobacco product surveillance identified ranged from reviews of tobacco industry documents and patents to survey studies to focus group research to analysis of retail scanner data. Because of the diverse range of methods utilized here, we take a qualitative, narrative approach to reviewing and synthesizing the literature.

Results

Surveillance Methods

Based on our review of existing literature, Table 2 shows the methods that have been or could be used to identify, characterize, and/or monitor new and modified tobacco products in the marketplace. The ultimate use of a PREP surveillance system would be to understand and/or determine impacts on public health.(41) However, methods for monitoring tobacco-related health effects will not be reviewed herein. Note that the relationship among the surveillance phases is not necessarily linear; that is, identification, and characterization could be accomplished simultaneously, for example. Each method had advantages and disadvantages, and these are listed in columns in Table 2, with elaboration below.

Table 2.

Potential sources of information regarding new and modified tobacco products.

Source Location Description Advantages Disadvantages Utility
Identify Characterize Monitor
Disclosures to governments www.ftc.gov/tobacco
http://www.mass.gov/dph/mtcp
http://www.sec.gov/edgar/searchedgar/companysearch.html
(See Appendix A for full list)
The last FTC report on cigarette yields was issued in 2000, covering brands tested in 1998. Later data can be requested under the Freedom of Information Act.
Massachusetts, Minnesota, and Texas require additional disclosure of product design features and smoke constituents such as nicotine in tobacco, ventilation, and smoking at alternate machine regimens.
State tax and finance departments require manufacturers to report the brands and/or varieties offered for sale in those states, pursuant to the Master Settlement Agreement.
The New York State Office of Fire Prevention and Control maintains a list of brand styles certified as compliant with the cigarette ignition propensity regulation.
Legal mandate
Product-level data in many cases
Standard Industrial Classification (SIC) codes exist for companies dealing in Tobacco Products (SIC 2100) or Cigarettes (SIC 2111).
Depending on required reporting cycle, data may not reflect currently available products.
Data fields limited by what was requested by law/regulation
X X X
Industry reports and communications Business Source
Hoovers
Stock analyst reports
Scientific meeting presentations
Important pieces of data to extract are launches, market share, profitability, total product sales by category (cigarettes, smokeless, other), and profit margin. Databases exist
Designed for others in the industry and/or investors
Time and effort needed to extract data
At best hypothesis generating
X X X
Internet Various Novel products may have dedicated websites with product information.
Examine possible viral marketing on the web, via chat rooms, blogs, message boards, YouTube, and social networking sites (e.g., MySpace; Facebook).
May gain direct insights from consumers Difficult to determine accuracy/reliability of information
Particularly difficult separating ‘stealth’ comments made by marketers from legitimate consumer postings.
X X X
Local Area Tracking N/A The distinction between national rollout and local test markets can be important.
States routinely perform compliance checks of retailers’ youth sales practices under the Synar Amendment, which might provide an opportunity to examine the brand mix and pricing strategies in retail environments.
Assess point of purchase, a key marketing point
Know what is available in a given market
Allows data gathering for characterization of packaging, claims, and product engineering
Coordination needed to ensure coverage of different retail environments
Labor intensive
X X X
Newspapers Lexis-Nexis CDC created a system to track tobacco-related news stories in 2004, so in principle it is feasible. Databases search major domestic and international newspapers, and even TV and radio transcripts Labor intensive
Requires pre-coded evaluation and abstracting
X X X
Patents http://www.uspto.gov/patft/index.html
http://www.google.com/ptshp?tab=wt
http://www.espacenet.com/index.en.htm
The USPTO allows searches of published patent applications from March 1991 forward. Technically descriptive
Requirement to describe prior art
Difficult to link to specific products
May never be commercialized
May contain misleading/incorrect information
X X
Internal Tobacco Industry Documents www.tobaccodocuments.org
legacy.library.ucsf.edu
www.pmdocs.com
www.rjrtdocs.com
www.lorillarddocs.com
As a result of the Master Settlement Agreement (MSA), the major cigarette companies are required to disclose among other things internal reports and research on their products. Required disclosure
Little motivation to mislead internally
Availability of developmental work, laboratory notebooks, testing data
Lag between creation and release
May reflect older thinking
Some product specific information (such as brand formulas) may be considered proprietary and not made available.
Incomplete record
X X
Correspondence with the company www.altria.com
www.philipmorrisusa.com
www.reynoldsamerican.com
www.lorillard.com
www.ustinc.com
Massachusetts Tobacco Control Program has held meetings with tobacco manufacturers in an effort to learn about new product offerings such as Marlboro UltraSmooth, Taboka, Marlboro Snus, and Marlboro Moist Snuff. Ability to ask targeted, direct questions
May gain information not otherwise publicized
No guarantee of (truthful) response
May be provided misleading information
X X
Informants N/A Former and current company employees, assuming they are not bound by confidentiality agreements, may be able to describe ongoing research in general terms.
Wholesalers, distributors, and retailers may also be aware of upcoming product launches, and may also be able to provide advance notice.
May gain information not otherwise publicized No guarantee of accuracy of information X X
Products introduced in international markets http://www.tobaccojournal.com/ The major tobacco companies operate in multiple countries via partnerships, licensing agreements, and subsidiaries. Actual products and associated marketing to examine Product may fill a localized product niche, and stand little chance of being sold in US X X
Trade publications www.tobaccoreporter.com
www.tobaccojournal.com
http://www.tma.org/tmalive/FrmMain
Trade publications include Tobacco Reporter, Tobacco Journal International, Smokeshop, and Tobacco International.
The Tobacco Merchants’ Association (TMA) has extensive databases of product information that may be purchased by interested parties.
Information directly from and for those commercially interested in the products May require corroboration from independent sources
Require subscriptions
Costly
X X
Magazine Advertising http://www.smrb.com/
http://www.mediamark.com/
http://www.nielsenmedia.com/nc/portal/site/Public/
http://www.tns-mi.com/
Magazine advertising data is available from independent commercial data sources for consumer products such as Simmons Market Research, Mediamark Research Inc., TNS Media Intelligence (TNS), TwelvePlus, and DoubleBase.
Key variables
Readership demographics
Advertising volume
Expenditures
Placement information (magazine title, issue date, brands advertised, list price)
Databases exist, and customized datasets can be ordered Magazine advertising of cigarette products less common than in the past
Costly
X X
Sales and Use http://www.nielsenmedia.com/nc/portal/site/Public/ Commercial databases track consumer products including tobacco products for sale and price by sub-brand nationally and in selected markets that can be used to measure use and compare to conventional products and control for manufacturer’s manipulation of price to affect sales. Objective data on purchasing patterns
Ability to examine trends
May not include certain retail outlet categories (e.g., convenience stores)
Costly.
Little insight into reasons for purchase
X
Population surveys http://www.oas.samhsa.gov/nhsda.htm
http://www.cdc.gov/nchs/nhanes.htm
http://www.cdc.gov/nchs/nhis.htm
http://www.monitoringthefuture.org/
Brand and sub-brand level tobacco use data are obtained from a number of national and statewide tobacco surveys or other surveys with tobacco modules or questions, including the National Survey on Drug Use and Health, Monitoring the Future Survey, National Health and Nutrition Examination Survey, and the National Health Information Survey. Representative samples
Samples generally large enough to examine test marketing in limited geographic areas
Limited brand information, if any
Can only ask limited set of questions about any given topic
Difficult to field for quick response to emerging product
X
Focus groups Gather small groups of consumers to gain information about product perceptions. Can be fielded rapidly in response to new products
Opportunity for more in-depth questionning
Can serve to inform other data collection modalities (e.g., surveys)
Tend to be unrepresentative
Time consuming
X

Reliability and Validity

Surveillance of tobacco products has relied in large part upon proxy data collected for other purposes. In general, the reliability and validity of the methods, in the traditional psychometrics sense, have not been established. Table 3 lists ways in which such data collection systems could in principle be assessed in terms of traditional reliability and validity criteria, though very little formal work has been done in this area. The strengths and weaknesses of these individual systems is described in more detail in the following sections of the paper. In general, methods involving coders to categorize or abstract text-based data (e.g., industry documents; newspaper articles) should rely on pre-determined coding schemes, with a target inter-coder reliability of at least 85%. More quantitative data (e.g., contents and emissions, sales) can be checked against results from other sources, historical trends, or gold standards as appropriate. Assessing the overall reliability and validity of proxy measures broadly falls under the concept of triangulation(42). Triangulation refers to the principle of using multiple data sources and methodologies to study the same phenomenon, in this case PREP identification, characterization, and monitoring. The multitrait-multimethod matrix is one approach to triangulation created by Campbell and Fiske (43)to assess construct validity using distinct reliable and valid measures of an underlying trait or traits, to assess the proportion of variance in measure accounted for by trait versus method. Houston (44) has proposed a construct validation for proxy data using a three-stage process: 1) Theoretical specification; 2) Measurement property assessment; 3) Nomological validity. In order to assess the validity of the proxy data in question, one must have a working theory of how the measures do and do not relate to the surveillance outcome (e.g., PREP use prevalence), and a good sense of the measurement properties (e.g., reliability, repeatability) of the proxies. Nomological validity, then, refers to the degree to which a measure(s) of a construct relates to other measures in a way that is consistent with the underlying theory.(44) While performing such validation is beyond the scope of this paper, we would recommend that the measures identified be subjected to this sort of inquiry prior to use in a surveillance system.

Table 3.

Concepts in reliability and validity assessment for potential product-level surveillance methods

Source Method(s) Reliability Validity
Patents Keyword search; content analysis; patent mapping Consistency across searchers (agreement > 85%); prespecified search terms Predictive (e.g., does a PREP come to market relying on a patent identified as important?)
Internal Tobacco Industry Documents Keyword search; semiotics; content analysis Trained, blinded coders; systematized prespecified categories; inter-coder agreement > 0.85 Convergent (e.g., does preliminary data in documents associate with patents or marketed products?)
Industry reports and communications Content analysis prespecified search terms Face
Government Reports Content analysis prespecified search terms Face
Correspondence with the company Interviews; questionnaires NA Face;
Informants Interviews NA Convergent (do different informants give similar information?)
Products introduced in international markets Keyword search, interviews, questionnaires prespecified search terms Predictive (e.g., does the foreign product or similar technology eventually appear on the US market?)
Government databases Frequency analysis NA Face
Trade publications Content analysis prespecified search terms
Magazine Advertising Readership demographics
Advertising volume
Expenditures
Placement information
Content analysis
Semiotics
Trained, blinded coders; systematized prespecified categories; inter-coder agreement > 0.85; sourcing from multiple companies Predictive (e.g., do advertising expenditures and ad content lead to increases in sales or beliefs about product safety?)
Internet Keyword search; content analysis; semiotics Trained, blinded coders; systematized prespecified categories; inter-coder agreement > 0.85 Convergent (e.g., do blog postings about products correspond to sales and use data for those products?)
Sales and Use Scanner data
Tax receipts
NA Convergent (e.g., do sales data and reported use correlate positively?)
Local Area Tracking Synar inspections; retailer licensing NA Convergent (e.g., does product availability at retail correspond to sales and usage data?)
Population usage Mall intercept; RDD; web survey; panels; focus groups Test-retest; internal consistency; Face; predictive; convergent; divergent

Phase I - Identifying products

An approach to identifying products consists of 1) having intelligence regarding what PREP products are under development and have a reasonable chance of coming to market, and 2) knowing when products come onto the market. Under a comprehensive regulatory system for tobacco and nicotine products, new products and related claims could be required to undergo a pre-market approval process, including disclosure of information about product characteristics and related research. However, in the absence of regulation, outside data sources are necessary to aid the identification of new products.

Strategies used by corporations to assess competitors, sometimes called competitive intelligence (CI)(45), may provide a useful model for informing public health approaches to PREP surveillance. CI, generally, refers to systematically gathering, analyzing, and applying available information about other companies’ products, markets, customers, and competitors in order to facilitate planning for one’s own company, with the aim of gaining a competitive advantage. For example, a Philip Morris USA Research and Development strategic plan for 1993–1997 devotes several pages to in-depth analysis of the activities of the company’s closest competitors (RJ Reynolds, Brown and Williamson, Japan Tobacco), including listings of patents awarded to each company, with analysis of how these might be used commercially.(46) This information can be gathered any number of ways, but, generally, begins with publicly available information (e.g., websites, government filings, patents, and news stories), and then moves toward primary research (e.g., testing and reverse engineering products, tracking sales, networking, and trade shows). Other sources of such information are business databases (e.g., Business Source; Hoovers), where SWOT (Strengths, Weaknesses, Opportunities, Threats) analyses, competitor analyses, and patent attainments can be searched simultaneously for specific companies. While the ultimate aims of public health surveillance may be different from those of business CI, some of these methods may be used to advance public health.

Information on patents registered with the US Patent and Trademark Office (USPTO) can potentially serve as a source of information on new products prior to their introduction. Patents can be granted on any inventions that are novel, unobvious, and useful. Individuals and companies, to protect new ideas and technologies through patent applications, must include a discussion of all ‘prior art’ related to the described invention (including foreign patents and non-patent literature), and so, these citations provide a means to identify similar and related developments. Patents may contain information that has yet to appear, or may never appear, in the published literature.(47) A way to make sense of patents related to PREPs is to construct Patent Maps, or a graphic illustration of interactions among different patents by a single company or across multiple companies.(48) A patent map is most often focused on interrelationships between a given patent of interest and others that are related to it in some way (e.g., prior art; subsequent art; complementary processes), often built using other patents cited in the target patent. Seeber (47) recently provided a useful overview on patent searching for life sciences researchers. A potential drawback to patents is that they may contain false or misleading information. Companies may also secure patents on technologies they have no intention of commercializing, sometimes in order to prevent a competitor from coming to market with similar technologies. Both of these are risks in using patents to identify PREPs.

Internal industry documents can provide important additional context on the development of new and modified products, by providing data on product characteristics and allowing better focus on further search strategies. Internal documents have been a rich resource on the industry’s research and development practices for novel products. Public health researchers have made use of documents and patents in characterizing products such as Barclay, Premier, Eclipse and Marlboro Ultrasmooth, as well as research programs into nicotine analogues, and design innovations such as filters, flavor pellets and additives to mask environmental tobacco smoke odor.(13;33;4964) Recommended methods exist for searching and analyzing internal tobacco industry documents, which can aid in reliability and validity of findings.(6567) However, industry documents made available through litigation may not necessarily provide comprehensive information on particular product or related industry activities; thus, these documents must be interpreted with caution, though they can provide essential information not available through other sources. (68)

Marking the release of new products can be as simple as checking what is for sale on store shelves.(69) Press releases or other official communications (e.g., Annual Reports) from companies may also reveal plans for recent and/or upcoming product releases. This can provide a justification to directly request information from tobacco companies or informants, a low cost, albeit ad hoc, means of learning about new technologies and products. Publicly traded companies in the US must also file quarterly and yearly reports with the Securities and Exchange Commission, and these will contain information about upcoming initiatives expected to influence profits and losses. New product launches, performance of current product mix, and other information will, generally, be included. Companies may also meet with stock analysts from investment banks (e.g., Citigroup, Deutsche Bank) and present new initiatives, so stock analysts’ reports of those companies may provide information about future plans. We could identify no published scientific reports making use of such data, but stock analyst reports, new product launches, and similar data are often reported in trade publications. Major companies have also presented information about new products at scientific meetings. The reliability and validity of such information is hard to judge, depending heavily on the credibility of the source, so these data might be best considered hypothesis generating.

Finally, noting the introduction of new products in markets outside the US may, in some instances, provide an early view of new product technologies that may, eventually, be introduced in the US. The major US companies are multinational, and/or have overseas partnerships and distribution agreements. So, it is reasonable to believe that a product marketed in other countries could be introduced into a US market that remains highly profitable. However, the converse may also be the case—companies may preferentially introduce novel products into growing markets.

Phase II - Characterizing products

As the World Health Organization’s (WHO) Scientific Advisory Committee on Tobacco (34) noted, “The first logical step in examining a product having potential to reduce the harm produced by tobacco use is to examine the characteristics of the product.” This entails examining both the characteristics of the product itself and the manufacturers’ claims about the product2. By nature, the specific steps to be taken are heavily dependent on the product in question. This paper reviews those methods most suited to ongoing surveillance of PREPs.

Tobacco manufacturers routinely examine and reverse engineer one another’s products, particularly to gain information about novel product innovations.(55;56;7072) An example is the Barclay 1mg FTC tar cigarette introduced by Brown and Williamson in 1980. Because of its claims of low tar and reports of significant taste improvement relative to other 1mg products, Philip Morris and RJ Reynolds reverse engineered the product and within days discovered how the Actron filter ‘cheated’ the FTC regimen, resulting in a lawsuit over the 1mg FTC yield claim.(56) There are useful lessons for public health science in understanding how tobacco manufacturers conduct rapid and ongoing assessments of competitor products.

Characteristics

The first level of analysis in assessing product design requires determination of whether the product is a combustible or noncombustible product, which can, generally, be accomplished by visual inspection. Clearly, there are differences in product characteristics, as well as potential risks, between combustible and noncombustible tobacco products.(73;74) Products that do not fall neatly into one or the other category (e.g., Eclipse and Accord) may need to be considered as a separate product class.

Previous investigations of combustible product characteristics have largely focused on tar, nicotine, carbon monoxide, and other toxicant emissions as measured by smoking machines,(7580) or use in vivo in clinical studies,(8188) with less attention to the more basic aspects of physical design and packaging. (80;89;90) However, when product design and context are not considered, findings from smoke chemistry and even clinical studies can be misleading, as in the case of filter ventilation and Light cigarettes, for example.(14;15;34;91) Combustible tobacco products can also be characterized for design features such as filter construction (e.g., length, weight, density, presence and type of charcoal), ventilation, and paper permeability.(80;90;92) The WHO Study Group on Tobacco Product Regulation (35) has recommended mandated reporting on aerosol particle size, filter ventilation, filter length, filter fiber residues, filter charcoal content, cigarette circumference, paper porosity, % reconstituted tobacco, % expanded tobacco, moisture content, and product firmness (an indicator of tobacco density). For some of these, internationally adopted standard methods exist (e.g., ISO 15152:2003 for nicotine, 6565:2002 for pressure drop, and 2965:1997 for paper permeability). For others (e.g., assessment of blend composition; filter fiber residues), developmental activities would be necessary. The TobReg list of characteristics would seem to be useful for PREP surveillance, though it presumes a cigarette-like construction with a filter.

For non-combusted products, form (loose, pouch, tablet), nicotine content, moisture, and pH (which influences free nicotine availability) are key characteristics and can be measured relatively simply using established methods. (93) A number of smokeless tobacco products exist (chew, dry snuff, moist snuff, pouches, and Swedish-style snus). Tobacco-specific nitrosamines are also a major concern and are commonly measured (9496) though other toxins such as metals and PAHs are concerning. A significant gap in testing smokeless tobacco products is the wide variation in tobacco moisture and humectant levels, which makes weight adjusted-reporting of contents difficult, and therefore, makes comparisons across different smokeless products potentially unreliable.

A basic physical analysis can provide qualitative and quantitative data about general product differences, but will not necessarily provide specific data about any of the novel features themselves, nor their impacts on product performance. One may find it necessary then to test smoke chemistry to examine specific toxicant emissions,(97104) other tobacco contents,(105109) tobacco mutagenicity,(110;111) or the targeted reverse engineering of design elements.(59;64;80;112) Exactly what would be measured at this stage would rely heavily on hypotheses generated by the physical analysis and information gleaned from patents and product claims. Creative reverse engineering can explore more novel aspects of particular products such as the flavor-laden beads in Camel Exotic Blends,(52) the charcoal beads in Marlboro Ultrasmooth,(80) and the menthol capsule in the newly-released Camel Crush.(113)

The reliability and validity of certain standardized laboratory tests of tobacco products themselves (that is, assay validity) have largely been established by groups such as the International Organization for Standardization (ISO). Interlaboratory variability in measures, as well as inherent variability in products, can lead to different results on repeated testing, which highlights the need to rely on several data points rather than a single test in characterizing a new product.

Claims

One way to determine how something is new or may be a PREP is to examine what the manufacturer is saying about the product. Currently, tobacco companies lack a priori restrictions on product claims because no legally required pre-market approval or review exist. Some manufactures have made seemingly explicit health claims, e.g., Eclipse ("responds to concerns about certain smoking-related illnesses … including cancer." And “The best choice for smokers who worry about their health is to quit. The next best choice is Eclipse.").(114) In most cases, however, PREP products are not accompanied by explicit health claims, but by more subtle messages that communicate aspects of taste, enjoyment, or technological features.(115) For example, manufacturers may tout a new filter technology (e.g., Marlboro Ultrasmooth), spit-free (Camel Snus), additive-free (Winston; American Spirit), or improved taste. There is evidence that consumers, nevertheless, perceive such implicit or non-specific claims as health messages.(116120)

Product claims (both implicit and explicit) are commonly conveyed via advertising and other marketing materials as well as through the product packaging and characteristics. Content analysis of product advertising (31;61;65;121) has been used in the past to highlight themes. For more novel products, instructions on how to use the product may be included within advertising or promotional material (e.g., dosing instructions for Camel Snus and Eclipse).

Three marketing channels that should be monitored for claims are mailing lists, point-of-sale advertising, and internet. Mailing lists allow companies to directly target smokers, as well as specific sub-segments of smokers who are believed to be more receptive to the new product. Mailings may include coupons, bonus items, or other inducements to try the product,(122124) and also may include information about the product not presented in more public media. Point of sale advertising is associated with impulse purchasing,(125) and so can serve as a stimulus to try a new product. Examining the prevalence and content of retail advertising can also be important to assessing the likely success of a new product, and methods for this type of tracking exist.(126131) Tobacco advertising on the internet is growing and many smokers report seeing ads.(132) Companies may create dedicated websites for new products 3,4as a means to convey more detailed information than could be contained in either direct mail or point of sale promotions. For example, the Camel Snus website (at the time of this writing) features a video demonstrating how and where to use the product.

The product package being the ultimate advertisement (133135) is often the most prominent visual and tactile incarnation of the brand identity, and in the US is prominent in the retail environment. Therefore, examining packaging is a critical component to characterizing new brands. To set new brands apart, new color schemes, packaging designs (nontraditional sizes, new shapes, new materials), and number of units per package may be manipulated. Descriptive words or statements may also be important indicators of potential claims. Another potential form of communication relevant to product claims can be product ‘onserts’ or small booklets attached to packages. PMUSA, for example, has placed informational onserts on some regular brands, as well as on their Ultrasmooth, Taboka, and Marlboro Snus products.5 Some of these onserts describe the product, how to use the product, general information about health risks, or interpreting emissions numbers. These represent another avenue by which manufacturers convey information to consumers.

Claims can be collected systematically by having raters purchase and catalogue products and their associated advertising and marketing materials using a predetermined coding scheme. Raters would need to make note of the specific text of claims and make a determination as to which of a number of fixed categories it best fits. Other objects such as coupons, onserts, and free offers could be coded as to presence/absence, as well as content. Methods for qualitative analysis of documents and advertising, such as content analysis and semiotics,(65;136) can be employed here to ensure systematicity and objectivity. Recording the package Universal Product Code (UPC) is potentially critical--these are used by manufacturers to track inventory and sales of particular varieties. This would also allow one to more accurately follow a particular brand, as well as facilitating linkage of these data to other databases.

Phase III - Monitoring products introduced into the marketplace

Publicly available sources of data that can be applied to track brands include state brand registration lists related to the Master Settlement Agreement, as well as mandated certification of brand styles under cigarette ignition propensity (‘fire-safe’) regulations. A list of state MSA brand registration lists is included in Appendix A. These lists may be updated periodically.

Tobacco industry trade publications such as Tobacco Reporter, Tobacco Journal International, and Tobacco International may discuss new products and may even give preliminary data on usage and uptake. These are searchable in business literature databases such as Business Source. A drawback to trade journals is that information quality may depend on the sources used.

News stories may be a way to track introductions and adoption of products. Publicly available databases such as Lexis/Nexis can be used to identify stories published in daily national newspapers (e.g., New York Times, Washington Post, Wall Street Journal). These databases may offer searching capabilities for television and radio transcripts, and international newspapers, offering an additional line of inquiry. The Office on Smoking and Health at the CDC created a surveillance system for tobacco-related news stories in 2004,(137) and this could be routinized to serve as a platform for identifying stories about new products. News tracking, however, is labor intensive and requires pre-coded schemes for classifying and abstracting stories.

Tracking magazine advertising, which can be accomplished via commercial services, can provide insight into the marketing campaigns for products, including who might be target audiences. These data sources also provide important information about the demographics of magazine readership which can be explored to determine who the product advertising is being marketed to (age, sex, race). Reed et al.(138) showed that historical trends in magazine advertising for light cigarettes were predictive of increases in market share of these cigarettes, illustrating the utility of secondary data sources for tracking the adoption of new products. However cigarette companies have become less reliant on print advertising, shifting to other areas of promotion,(139) so, the relevance of tracking magazine advertising has diminished.

Sales data can be very important to determining whether a brand is gaining significant market share.(140) A valuable format is retail scanner data, which investigators have used to examine sales trends.(141;142) A potential drawback of scanner data is that it reflects purchases but provides no process data(143)—it tells one nothing of why a consumer bought the PREP at that time—and also that scanner data may only be available for a select group of participants or purchase locations, raising issues of representativeness.(143)

Integration

Data sets representing market, advertising, and tobacco use information can be merged by UPC. For example, market share, sales, and price data for a certain year could merged with nicotine yield and other product design data from the corresponding year in the Massachusetts Department of Public Health mandated reporting data, as well as magazine advertising placements data. This linkage across multiple data sources could give a more complete picture of the place of a PREP in the market.

Assessing awareness and adoption

Once a product is in the marketplace, surveillance of product awareness and uptake becomes essential to establishing whether a product may have a public health impact.(117;118;144151) Issues of population surveillance for the adoption of PREPs and consumer perceptions thereof have been covered by other authors in greater detail.(152–153)6,7 The large national surveys where brand use information is available (National Survey on Drug Use and Health; National Health and Nutrition Examination Survey) can serve an important surveillance function for tracking long term trends in tobacco products, particularly, PREPs. However, these large surveys take years to develop and implement in the field, making them less valuable for tracking short-term changes in the market. An alternative to population surveys is focus groups, wherein small groups of consumers similar on some characteristic(s) provide reactions to products and marketing materials.(154;155) While weak in terms of generalizability and representativeness, these groups provide an opportunity to ask more detailed questions about products than could be achieved in a survey.

The Internet can be potentially valuable in tracking adoption – users of new products may post comments on blogs or social networking sites,(156158) which may provide some insight into consumer reactions. Google searching and passive monitoring of tobacco-related chatrooms, message boards, and blogs can provide interesting data related to new product usage directly from users. Indeed, some scientists have made similar recommendations concerning the misuse of prescription medications.(159) Eclipse was intended to be marketed in part by ‘viral’ means.(49) Viral marketing, as commonly defined, seeks to exploit pre-existing social networks to increase awareness or sales of products, usually by having consumers voluntarily disseminate a marketing message.(160) A subset of viral marketing, stealth (also known as guerilla or buzz) marketing, often hijacks a social network by use of undercover ‘shills’ paid to make positive comments about a product.(158) Systematic assessment of internet postings is an emerging discipline. Particularly difficult would be separating out ‘stealth’ comments made by marketers from legitimate ones made by consumers. However, like much qualitative research, reliability and generalizability would depend heavily on good training of raters, consistent coding criteria, and systematic synthesis of information from multiple sources.(65;68)

Discussion

This paper has reviewed the strengths and weaknesses of a range of different data sources for studying and tracking PREPs. While the various information sources described have their own strengths and weaknesses, there are some overarching challenges for surveillance that emerge from the review. First, a significant gap is the lack of a formal investigation into the reliability and validity of these data sources. Second, while mandated government disclosure has the potential to be a vital and comprehensive source of information about products, current disclosure requirements are limited. Thus, the value of some types of data is diminished by the lack of a formalized, legally mandated mechanism for reporting. Third, there is no single data source that is alone sufficient for identification, characterization, and monitoring of PREPs. Rather, a range of data sources are needed.

The reliability and validity of the methods may depend on the contexts and purposes to which they are applied. As an example, focus group studies provide an opportunity for in-depth questioning unavailable in larger population studies, yet focus groups are generally regarded as a weaker methodology in terms of generalizability. Information from companies can serve to confirm findings of new products in retail monitoring, and claims made by companies can be confirmed or countered by data gathered from retail sales databases, focus groups, product reverse engineering, and/or surveys. Data required to be disclosed via regulation has the advantage of force of law, though it does not guarantee that the data is accurate, nor easy to decipher. Only independent monitoring can provide a comparator against which to assess mandated disclosures for accuracy and completeness. For example, product contents and emissions data provided by companies can be checked by sending product samples to an independent laboratory for testing. Reported marketing expenditures and sales volumes can be checked against databases such as Nielsen and Mediamark. However, these databases themselves are limited by the number, location, and types of retail outlets and publications from which they draw their data. So, clearly, no single one of these data streams is sufficient to characterize PREPs – multiple data sources must be collected and compared prior to coming to any judgments.

Nevertheless, these data sources can be prioritized to some degree within the contexts of PREP identification, characterization, and monitoring. Table 4 describes the key types of data that are needed for each context and the corresponding measures that are prioritized for that context. Priority data sources are those with the highest validity and reliability, while Secondary sources are those that can provide essential information but have methodological limitations. However, when Priority sources are not available, more reliance on Secondary sources may be necessary. For example, in the absence of government-mandated product constituent disclosures, more reliance may be needed on supplementary sources such as internal documents and patents for characterizing PREPs.

Table 4.

Priority Measures for Identification, Characterization, and Monitoring of PREPs.

Identification Characterization Monitoring
Key data Product name
Launch date(s) and
location(s)
Constituents and/or
emissions
Claims
Design
Marketing
Consumer
response/perception
Consumer uptake
Sales
Priority Sources Industry reports
Trade publications
Local tracking
Government disclosure
Independent scientific
testing
Sales and use data
Population surveys
Secondary Sources International market
Newspapers
Internet
Industry reports
Internal documents and patents
Correspondence
Newspaper articles
Industry reports
Newspaper reports
Magazine advertising
Government disclosures
Rationale In order to identify potential PREP-type products on the market, data sources should be highly sensitive (at the cost of specificity) and provide real time information. To effectively characterize PREP products, it is essential to have valid, independent information about the product’s characteristics. Monitoring requires reliable and consistent sources of information to identify trends and changes over time as well as the impact of products on the population (through tracking marketing and consumer perceptions).

Currently, scientists and public health officials lack a standardized approach for identifying, defining, and evaluating tobacco products available for sale to consumers at the local, state or national levels. This is a major gap both in tobacco control research and practice, as methods exist which could be used with greater frequency, coordination, and efficiency than they are currently. Groups such as the Global Tobacco Research Network8, Tobacco Harm Reduction Network9, and Tobacco Surveillance, Epidemiology, and Evaluation Network (TSEEN)10 have selectively tracked new products and their marketing. For example, various internet sites (e.g., Trinkets and Trash11; Campaign for Tobacco Free Kids;12 Tobacco Products Wiki13, CigarettesPedia14) have attempted to catalogue and track products and marketing. However, such sites do not provide comprehensive surveillance or track innovation and new products development, branding, and market segmentation (demographic and geographic). The changing tobacco product marketplace requires surveillance in order to identify trends so that public health agencies can respond to new developments in products which could impact population health.

A recent series of papers emerging from the 2002 National Tobacco Monitoring, Research, and Evaluation Workshop (3640) provides an excellent overview of the state of the science on tobacco surveillance broadly. The group deconstructed surveillance activities using the classical Agent-Host-Vector-Environment epidemiologic model, and made specific recommendations as to short- and long-term goals for each area.(36) Among these were:

  • Develop a national tobacco surveillance clearinghouse for local, state, federal, and nonprofit agencies involved in conducting tobacco-related surveillance, research, and evaluation and in implementing tobacco control programs and policies.

  • Support a National Clearinghouse for Tobacco Promotion Information.

  • Begin surveillance of content and composition of unburned tobacco products; support research to identify toxicological assays for subsequent use in monitoring.

  • Develop best practices for identifying and collecting local laws; including timing, sample frame, and responsible practices for collection and analysis.(36)

A surveillance system for PREPs would ideally be embedded within this larger framework, integrating the different data sources so that information is available to define types of products available, their unique design features, information on how the products are marketed, and data on consumer perception and use. Of particular interest in the identification and tracking of PREPs include industry strategies such as brand innovation, product design, market segmentation, messaging, advertising and promotion, and pricing; and the individual and combined effects of the various marketing approaches on the population. Given recent proposals to regulate the toxicity of tobacco products,(12;161) a systematic surveillance system for PREP tobacco products will provide critical baseline information to inform regulatory efforts and further monitoring.

A natural question arises as to whom the responsibility falls to coordinate PREP surveillance. Given that most PREPs tend to be introduced locally, rather than nationally, state health departments would appear to be the ideal loci for such activities. States already conduct local surveillance of adult and youth smoking prevalence and youth sales compliance, so adding product monitoring and support for other activities described herein, even if only in a coordinating role, would be helpful in getting a system up and running. This is in keeping with the Tobacco Use Monitoring Workshop recommendation vis a vis best practices for local evaluation and monitoring.(36) While this paper has evaluated and prioritized the available data sources for surveillance, further work is needed to determine the best mechanisms for implementing these surveillance methods in practice.

Conclusions

PREPs are a growing concern to tobacco control advocates. However, thus far, methods for monitoring the introduction, characteristics, and marketing of these products have been sporadic and not well integrated. A systematized approach to identify, characterize, and monitor PREPs and other novel tobacco products is needed, and steps are being taken to bring such a system to fruition.(3640) However, gaps related to the reliability and validity of secondary data sources must be overcome before such a surveillance system could be effectively implemented. By systematizing the collection of information about tobacco products offered for sale, ideally, at the state or local level, public health officials can better understand the milieu in which smokers are immersed and better understand smokers’ behavior and the potential implications for public health.

Supplementary Material

1

Acknowledgments

Funding. These activities were supported by National Cancer Institute contract HHSN261200644002 (Laboratory Assessment of Tobacco Use Behavior and Exposure to Toxins Among Users of New Tobacco Products Promoted to Reduce Harm).

Footnotes

2

A full and detailed review of all possible methods for characterizing product contents, emissions, and biobehavioral effects is beyond the scope of this paper.

6

Bogen K, Biener L, Garrett CA, Allen J, Cummings KM, Hartman A, Marcus S, McNeill A, O’Connor RJ, Parascandola M, Pederson L (submitted manuscript). Surveillance indicators for potential reduced exposure products (PREPs): developing survey items to measure awareness. Harm Reduction Journal.

7

Connolly G, Rees VW, Kreslake JM, O'Connor R, Cummings KM (submitted manuscript). Assessing consumer response to PREPs: A review of tobacco industry and public health methods. Cancer Epid Biomarkers.

Reference List

  • 1.Last JM. Dictionary of Epidemiology. 3rd ed. New York: Oxford University Press; 1995. [Google Scholar]
  • 2.Giovino GA, Schooley MW, Zhu BP, et al. Surveillance for selected tobacco-use behaviors--United States, 1900–1994. MMWR CDC Surveill Summ. 1994;43:1–43. [PubMed] [Google Scholar]
  • 3.Giovino GA. Epidemiology of tobacco use in the United States. Oncogene. 2002;21:7326–7340. doi: 10.1038/sj.onc.1205808. [DOI] [PubMed] [Google Scholar]
  • 4.Giovino GA. The tobacco epidemic in the United States. Am J Prev Med. 2007;33(6 Suppl):S318–S326. doi: 10.1016/j.amepre.2007.09.008. [DOI] [PubMed] [Google Scholar]
  • 5.Cummings KM, Hyland A, Lewit E, Shopland D. Discrepancies in cigarette brand sales and adult market share: are new teen smokers filling the gap? Tob Control. 1997;6(Suppl 2):S38–S43. doi: 10.1136/tc.6.suppl_2.s38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Cummings KM, Hyland A, Lewit E, Shopland D. Discrepancies in cigarette brand sales and adult market share: are new teen smokers filling the gap? Tob Control. 1997;6(Suppl 2):S38–S43. doi: 10.1136/tc.6.suppl_2.s38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cummings KM, Hyland A, Pechacek TF, Orlandi M, Lynn WR. Comparison of recent trends in adolescent and adult cigarette smoking behaviour and brand preferences. Tob Control. 1997;6(Suppl 2):S31–S37. doi: 10.1136/tc.6.suppl_2.s31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Changes in the cigarette brand preferences of adolescent smokers--United States, 1989–1993. MMWR Morb Mortal Wkly Rep. 1994;43:577–581. [PubMed] [Google Scholar]
  • 9.Comparison of the cigarette brand preferences of adult and teenaged smokers--United States, 1989, and 10 U.S. communities, 1988 and 1990. MMWR Morb Mortal Wkly Rep. 1992;41:169–181. [PubMed] [Google Scholar]
  • 10.Cigarette brand use among adult smokers--United States, 1986. MMWR Morb Mortal Wkly Rep. 1990;39:665, 671–665, 673. [PubMed] [Google Scholar]
  • 11.Siegel M, Nelson DE, Peddicord JP, Merritt RK, Giovino GA, Eriksen MP. The extent of cigarette brand and company switching: results from the Adult Use-of-Tobacco Survey. Am J Prev Med. 1996;12:14–16. [PubMed] [Google Scholar]
  • 12.Burns DM, Dybing E, Gray N, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob Control. 2008;17:132–141. doi: 10.1136/tc.2007.024158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hammond D, Collishaw NE, Callard C. Secret science: tobacco industry research on smoking behaviour and cigarette toxicity. Lancet. 2006;367:781–787. doi: 10.1016/S0140-6736(06)68077-X. [DOI] [PubMed] [Google Scholar]
  • 14.National Cancer Institute. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes. Bethesda: National Institutes of Health; 1996. [Google Scholar]
  • 15.National Cancer Institute. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Bethesda: National Institutes of Health; 2001. [Google Scholar]
  • 16.WHO Study Group on Tobacco Product Regulation. The Scientific Basis for Tobacco Product Regulation. Geneva: World Health Organization; 2007. [Google Scholar]
  • 17.Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the Smoke: the Science Base for Tobacco Harm Reduction. Washington, D.C: National Academy Press (Institute of Medicine); 2001. [Google Scholar]
  • 18.Fairchild A, Colgrove J. The Life, Death, and Rebirth of the "Safer" Cigarette in the United States. Am J Public Health. 1994;94:192–204. doi: 10.2105/ajph.94.2.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hatsukami DK, Giovino GA, Eissenberg T, Clark PI, Lawrence D, Leischow S. Methods to assess potential reduced exposure products. Nicotine Tob Res. 2005;7:827–844. doi: 10.1080/14622200500266015. [DOI] [PubMed] [Google Scholar]
  • 20.Warner KE. Tobacco harm reduction: Promise and perils. Nicotine & Tobacco Research. 2002:S61–S71. doi: 10.1080/1462220021000032825. [DOI] [PubMed] [Google Scholar]
  • 21.Warner KE. Will the next generation of "safer" cigarettes be safer? J Pediatr Hematol Oncol. 2005;27:543–550. doi: 10.1097/01.mph.0000184574.00717.6c. [DOI] [PubMed] [Google Scholar]
  • 22.Hatsukami DK, Henningfield JE, Kotlyar M. Harm reduction approaches to reducing tobacco-related mortality. Annu Rev Public Health. 2004;25:377–395. doi: 10.1146/annurev.publhealth.25.102802.124406. [DOI] [PubMed] [Google Scholar]
  • 23.Federal Trade Commission. Report of the Tar, Nicotine, and Carbon Monoxide of the Smoke of 1,294 Varieties of Domestic Cigarettes for the Year 1998. Washington, D.C: Federal Trade Commission; 2000. Ref Type: Report. [Google Scholar]
  • 24.Office of Fire Prevention and Control. New York State: Office of Fire Prevention and Control, Department of State; 2008. List of Cigarettes Certified by Manufacturers. http://www.dos.state.ny.us/fire/pdfs/cigaretteweb508.pdf. Ref Type: Electronic Citation. [Google Scholar]
  • 25.Connolly GN, Alpert HR. Trends in the use of cigarettes and other tobacco products, 2000–2007. JAMA. 2008;299:2629–2630. doi: 10.1001/jama.299.22.2629. [DOI] [PubMed] [Google Scholar]
  • 26.Delnevo CD, Hrywna M. "A whole 'nother smoke" or a cigarette in disguise: how RJ Reynolds reframed the image of little cigars. Am J Public Health. 2007;97:1368–1375. doi: 10.2105/AJPH.2006.101063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Nelson DE, Mowery P, Tomar S, Marcus S, Giovino G, Zhao L. Trends in smokeless tobacco use among adults and adolescents in the United States. Am J Public Health. 2006;96:897–905. doi: 10.2105/AJPH.2004.061580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Keller KL, Lehmann DR. Brands and branding: Research findings and future priorities. Marketing Science. 2006;25:740–759. [Google Scholar]
  • 29.Broniarczyk SM, Alba JW. The importance of the brand in brand extension. Journal of Marketing Research. 1994;31:214–228. [Google Scholar]
  • 30.Dacin PA, Smith DC. The effect of brand portfolio characteristics on consumer evaluations of brand extensions. Journal of Marketing Research. 1994;31:229–242. [Google Scholar]
  • 31.Pollay RW, Dewhirst T. The dark side of marketing seemingly "Light" cigarettes: successful images and failed fact. Tob Control. 2002;11(Suppl I):i18–i31. doi: 10.1136/tc.11.suppl_1.i18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Connolly GN, Alpert HR, Wayne GF, Koh H. Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997–2005. Tob Control. 2007;16:e5. doi: 10.1136/tc.2006.019695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Wayne GF, Connolly GN. How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983–1993. Tob Control. 2002;11(Suppl 1):I32–I39. doi: 10.1136/tc.11.suppl_1.i32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.WHO Scientific Advisory Committee on Tobacco Product Regulation. Geneva: World Health Organization; 2003. Statement of principles guiding the evaluation of new, or modified tobacco products. Ref Type: Report. [Google Scholar]
  • 35.WHO Study Group on Tobacco Product Regulation. Geneva: World Health Organization; 2004. Guiding Principles for the Development of Tobacco Product Research and Testing Capacity and Proposed Protocols for the Initiation of Tobacco Product Testing. Ref Type: Report. [Google Scholar]
  • 36.Giovino GA, Biener L, Hartman AM, et al. Monitoring the tobacco use epidemic I. Overview: Optimizing measurement to facilitate change. Prev Med. 2008 doi: 10.1016/j.ypmed.2008.08.007. [DOI] [PubMed] [Google Scholar]
  • 37.Stellman S, Djordjevic M. Monitoring the tobacco use epidemic II. The Agent: Current and Emerging Tobacco Products. Prev Med. 2008 doi: 10.1016/j.ypmed.2008.09.004. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Delnevo C, Bauer UE. Monitoring the tobacco use epidemic III. the host: Data sources and methodological challenges. Prev Med. 2008 doi: 10.1016/j.ypmed.2008.09.008. in press. [DOI] [PubMed] [Google Scholar]
  • 39.Cruz TB. Monitoring the tobacco use epidemic IV. The Vector: Tobacco Industry Data Sources and Recommendations for Research and Evaluation. Prev Med. 2008 doi: 10.1016/j.ypmed.2008.10.002. in press. [DOI] [PubMed] [Google Scholar]
  • 40.Farrelly MC. Monitoring the tobacco use epidemic V: Monitoring Environmental Factors That Influence Tobacco Use. Prev Med. 2008 doi: 10.1016/j.ypmed.2008.10.012. in press. [DOI] [PubMed] [Google Scholar]
  • 41.Hartman AM, Thun MJ, Ballard-Barbash R. Linking tobacco control policies and practices to early cancer endpoints: surveillance as an agent for change. Cancer Epidemiol Biomarkers Prev. 2008;17:2215–2219. doi: 10.1158/1055-9965.EPI-08-0563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Neuman WL. Social research methods. London: Pearson; 2003. [Google Scholar]
  • 43.Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychological Bulletin. 1959;56:81–105. [PubMed] [Google Scholar]
  • 44.Houston MB. Assessing the validity of secondary data proxies for marketing constructs. Journal of Business Research. 2004;57:154–161. [Google Scholar]
  • 45.Gordon I. Beat the Competition: How to Use Competitive Intelligence to Develop Winning Business Strategies. Oxford, U.K.: Basil Blackwell and Sons; 1989. [Google Scholar]
  • 46.Philip Morris USA. 1993–1997 Philip Morris USA R&D Strategic Plan. 2008 2021522925. Ref Type: Report. [Google Scholar]
  • 47.Seeber F. Patent searches as a complement to literature searches in the life sciences--a 'how-to' tutorial. Nat Protoc. 2007;2:2418–2428. doi: 10.1038/nprot.2007.355. [DOI] [PubMed] [Google Scholar]
  • 48.Singh V. Competitive Intelligence = Patent Analysis + Patent Mapping. Ezine Articles. 2008 Ref Type: Internet Communication. [Google Scholar]
  • 49.Anderson SJ, Ling PM. "And they told two friends…and so on": RJ Reynolds' Viral Marketing of Eclipse and Its Potential to Mislead the Public. Tob Control. 2008 doi: 10.1136/tc.2007.024273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Assunta M, Chapman S. A "clean cigarette" for a clean nation: a case study of Salem Pianissimo in Japan. Tob Control. 2004;13(Suppl 2):ii58–ii62. doi: 10.1136/tc.2004.008680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Carpenter CM, Wayne GF, Connolly GN. Designing cigarettes for women: new findings from the tobacco industry documents. Addiction. 2005;100:837–851. doi: 10.1111/j.1360-0443.2005.01072.x. [DOI] [PubMed] [Google Scholar]
  • 52.Carpenter CM, Wayne GF, Pauly JL, Koh HK, Connolly GN. New cigarette brands with flavors that appeal to youth: tobacco marketing strategies. Health Aff (Millwood) 2005;24:1601–1610. doi: 10.1377/hlthaff.24.6.1601. [DOI] [PubMed] [Google Scholar]
  • 53.Connolly GN, Wayne GD, Lymperis D, Doherty MC. How cigarette additives are used to mask environmental tobacco smoke. Tob Control. 2000;9:283–291. doi: 10.1136/tc.9.3.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Keithly L, Ferris Wayne G, Cullen DM, Connolly GN. Industry research on the use and effects of levulinic acid: a case study in cigarette additives. Nicotine Tob Res. 2005;7:761–771. doi: 10.1080/14622200500259820. [DOI] [PubMed] [Google Scholar]
  • 55.King B, Borland R. The "low-tar" strategy and the changing construction of Australian cigarettes. Nicotine Tob Res. 2004;6:85–94. doi: 10.1080/14622200310001656907. [DOI] [PubMed] [Google Scholar]
  • 56.Kozlowski Lynn T, Dreschel NA, Stellman SD, Wilkenfeld J, Weiss EB, Goldberg ME. An extremely compensatible cigarette by design: documentary evidence on industry awareness and reactions to the Barclay filter design cheating the tar testing system. Tob Control. 2005;14:64–70. doi: 10.1136/tc.2004.009167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Pauly JL, Allaart HA, Rodriguez MI, Streck RJ. Fibers released from cigarette filters: an additional health risk to the smoker? Cancer Res. 1995;55:253–258. [PubMed] [Google Scholar]
  • 58.Pauly JL, Stegmeier SJ, Mayer AG, Lesses JD, Streck RJ. Release of carbon granules from cigarettes with charcoal filters. Tob Control. 1997;6:33–40. doi: 10.1136/tc.6.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Pauly JL, Lee HJ, Hurley EL, Cummings KM, Lesses JD, Streck RJ. Glass fiber contamination of cigarette filters: an additional health risk to the smoker? Cancer Epidemiol Biomarkers. 1998;7:967–979. [PubMed] [Google Scholar]
  • 60.Pauly JL, Mepani AB, Lesses JD, Cummings KM, Streck RJ. Cigarettes with defective filters marketed for 40 years: what Philip Morris never told smokers. Tob Control. 2002;11(Suppl 1):I51–I61. doi: 10.1136/tc.11.suppl_1.i51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Pollay RW, Dewhirst T. Premiere example of the illusion of harm reduction cigarettes in the 1990s. Tob Control. 2003;12:322–332. doi: 10.1136/tc.12.3.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Vagg R, Chapman S. Nicotine analogues: a review of tobacco industry research interests. Addiction. 2005;100:701–712. doi: 10.1111/j.1360-0443.2005.01014.x. [DOI] [PubMed] [Google Scholar]
  • 63.Wayne GF. Potential reduced exposure products (PREPs) in industry trial testimony. Tob Control. 2006;15(Suppl 4):iv90–iv97. doi: 10.1136/tc.2004.009787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Pauly JL, Streck RJ, Cummings KM. US patents shed light on Eclipse and future cigarettes. Tob Control. 1995;4:261–265. [Google Scholar]
  • 65.Anderson SJ, Dewhirst T, Ling PM. Every document and picture tells a story: using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertising. Tob Control. 2006;15:254–261. doi: 10.1136/tc.2005.013854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Bero L. Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health. 2003;24:267–288. doi: 10.1146/annurev.publhealth.24.100901.140813. [DOI] [PubMed] [Google Scholar]
  • 67.Balbach ED, Barbeau EM. Beyond quagmires: the evolving quality of documents research. Tob Control. 2005;14:361–362. doi: 10.1136/tc.2005.014449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sandelowski M, Barroso J. Handbook for Synthesizing Qualitative Research. New York: Springer; 2006. [Google Scholar]
  • 69.Hickman N, Klonoff EA, Landrine H, et al. Preliminary investigation of the advertising and availability of PREPs, the new "safe" tobacco products. J Behav Med. 2004;27:413–424. doi: 10.1023/b:jobm.0000042413.69425.aa. [DOI] [PubMed] [Google Scholar]
  • 70.Philip Morris USA. C.I HIGHLIGHTS 941114. 1994 Ref Type: Report. [Google Scholar]
  • 71.Philip Morris USA. C.I HIGHLIGHTS 950300. 1995 Ref Type: Report. [Google Scholar]
  • 72.Smith KW. DRAFT Brand R&D Development Philosophy and Use of Non Consumer Test Data. 2-21-1994. RJ Reynolds Tobacco Company. Ref Type: Report. [Google Scholar]
  • 73.Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax. 2003;58:435–443. doi: 10.1136/thorax.58.5.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control. 2003;12:349–359. doi: 10.1136/tc.12.4.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Borgerding MF, Bodnar JA, Chung HL, et al. Chemical and biological studies of a new cigarette that primarily heats tobacco. Part 1. Chemical composition of mainstream smoke. Food Chem Toxicol. 2008;36:169–182. [PubMed] [Google Scholar]
  • 76.Counts ME, Hsu FS, Tewes FJ. Development of a commercial cigarette "market map" comparison methodology for evaluating new or non-conventional cigarettes. Regul Toxicol Pharmacol. 2006;46:225–242. doi: 10.1016/j.yrtph.2006.07.002. [DOI] [PubMed] [Google Scholar]
  • 77.deBethizy JD, Borgerding MF, Doolittle DJ, et al. Chemical and biological studies of a cigarette that heats rather than burns tobacco. J Clin Pharmacol. 1990;30:755–763. doi: 10.1002/j.1552-4604.1990.tb03639.x. [DOI] [PubMed] [Google Scholar]
  • 78.Laugesen M, Fowles J. Marlboro UltraSmooth: a potentially reduced exposure cigarette? Tob Control. 2006;15:430–435. doi: 10.1136/tc.2006.016055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Stabbert R, Voncken P, Rustemeier K, et al. Toxicological evaluation of an electrically heated cigarette. Part 2: Chemical composition of mainstream smoke. J Appl Toxicol. 2003;23:329–339. doi: 10.1002/jat.924. [DOI] [PubMed] [Google Scholar]
  • 80.Rees VW, Wayne GF, Thomas BF, Connolly GN. Physical design analysis and mainstream smoke constituent yields of the new potential reduced exposure product, Marlboro UltraSmooth. Nicotine Tob Res. 2007;9:1197–1206. doi: 10.1080/14622200701648375. [DOI] [PubMed] [Google Scholar]
  • 81.Breland AB, Evans SE, Buchhalter AR, Eissenberg T. Acute effects of Advance: a potential reduced exposure product for smokers. Tob Control. 2002;11:376–378. doi: 10.1136/tc.11.4.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Breland AB, Acosta MC, Eissenberg T. Tobacco specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of Advance. Tob Control. 2003;12:317–321. doi: 10.1136/tc.12.3.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Breland AB, Kleykamp BA, Eissenberg T. Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine Tob Res. 2006;8:727–738. doi: 10.1080/14622200600789585. [DOI] [PubMed] [Google Scholar]
  • 84.Hatsukami DK, Lemmonds C, Zhang Y, et al. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. J Natl Cancer Inst. 2004;96:844–852. doi: 10.1093/jnci/djh163. [DOI] [PubMed] [Google Scholar]
  • 85.Hatsukami DK, Lemmonds C, Tomar SL. Smokeless tobacco use: harm reduction or induction approach? Prev Med. 2004;38:309–317. doi: 10.1016/j.ypmed.2003.10.006. [DOI] [PubMed] [Google Scholar]
  • 86.Roethig HJ, Kinser RD, Lau RW, Walk RA, Wang N. Short-term exposure evaluation of adult smokers switching from conventional to first-generation electrically heated cigarettes during controlled smoking. J Clin Pharmacol. 2005;45:133–145. doi: 10.1177/0091270004271253. [DOI] [PubMed] [Google Scholar]
  • 87.Roethig HJ, Feng S, Liang Q, Liu J, Rees WA, Zedler BK. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol. 2008;48:580–591. doi: 10.1177/0091270008315316. [DOI] [PubMed] [Google Scholar]
  • 88.Roethig HJ, Zedler BK, Kinser RD, Feng S, Nelson BL, Liang Q. Short-term clinical exposure evaluation of a second-generation electrically heated cigarette smoking system. J Clin Pharmacol. 2007;47:518–530. doi: 10.1177/0091270006297686. [DOI] [PubMed] [Google Scholar]
  • 89.Slade J, Connolly GN, Lymperis D. Eclipse: does it live up to its health claims? Tob Control. 2002;11(Suppl 2):ii64–ii70. doi: 10.1136/tc.11.suppl_2.ii64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Kozlowski LT, Mehta NY, Sweeney CT, et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. Tob Control. 1998;7:369–375. doi: 10.1136/tc.7.4.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Kozlowski LT, O'Connor RJ. Cigarette filter ventilation is a defective design because of misleading taste, bigger puffs, and blocked vents. Tob Control. 2002;11(Suppl 1):I40–I50. doi: 10.1136/tc.11.suppl_1.i40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.O'Connor RJ, Hammond D, McNeill A, et al. How do different cigarette design features influence standard tar yields of popular cigarette brands sold in different countries? Tobacco Control. doi: 10.1136/tc.2006.019166. In press. [DOI] [PubMed] [Google Scholar]
  • 93.Richter P, Spierto FW. Surveillance of smokeless tobacco nicotine, pH, moisture, and unprotonated nicotine content. Nicotine Tob Res. 2003;5:885–889. doi: 10.1080/14622200310001614647. [DOI] [PubMed] [Google Scholar]
  • 94.Stepanov I, Hecht SS, Ramakrishnan S, Gupta PC. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. Int J Cancer. 2005;116:16–19. doi: 10.1002/ijc.20966. [DOI] [PubMed] [Google Scholar]
  • 95.Stepanov I, Jensen J, Hatsukami D, Hecht SS. Tobacco-specific nitrosamines in new tobacco products. Nicotine Tob Res. 2006;8:309–313. doi: 10.1080/14622200500490151. [DOI] [PubMed] [Google Scholar]
  • 96.Hoffmann D, Djordjevic MV, Fan J, Zang E, Glynn T, Connolly GN. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst. 1995;87:1862–1869. doi: 10.1093/jnci/87.24.1862. [DOI] [PubMed] [Google Scholar]
  • 97.Ding YS, Ashley DL, Watson CH. Determination of 10 carcinogenic polycyclic aromatic hydrocarbons in mainstream cigarette smoke. J Agric Food Chem. 2007;55:5966–5973. doi: 10.1021/jf070649o. [DOI] [PubMed] [Google Scholar]
  • 98.Polzin GM, Kosa-Maines RE, Ashley DL, Watson CH. Analysis of volatile organic compounds in mainstream cigarette smoke. Environ Sci Technol. 2007;41:1297–1302. doi: 10.1021/es060609l. [DOI] [PubMed] [Google Scholar]
  • 99.Ding YS, Yan XJ, Jain RB, et al. Determination of 14 polycyclic aromatic hydrocarbons in mainstream smoke from U.S. brand and non-U.S. brand cigarettes. Environ Sci Technol. 2006;40:1133–1138. doi: 10.1021/es0517320. [DOI] [PubMed] [Google Scholar]
  • 100.Pappas RS, Polzin GM, Zhang L, Watson CH, Paschal DC, Ashley DL. Cadmium, lead, and thallium in mainstream tobacco smoke particulate. Food Chem Toxicol. 2006;44:714–723. doi: 10.1016/j.fct.2005.10.004. [DOI] [PubMed] [Google Scholar]
  • 101.Watson CH, Trommel JS, Ashley DL. Solid-phase microextraction-based approach to determine free-base nicotine in trapped mainstream cigarette smoke total particulate matter. J Agric Food Chem. 2004;52:7240–7245. doi: 10.1021/jf049455o. [DOI] [PubMed] [Google Scholar]
  • 102.Wu W, Ashley DL, Watson CH. Simultaneous determination of five tobacco-specific nitrosamines in mainstream cigarette smoke by isotope dilution liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Chem. 2003;75:4827–4832. doi: 10.1021/ac030135y. [DOI] [PubMed] [Google Scholar]
  • 103.Stanfill SB, Ashley DL. Quantitation of flavor-related alkenylbenzenes in tobacco smoke particulate by selected ion monitoring gas chromatography-mass spectrometry. J Agric Food Chem. 2000;48:1298–1306. doi: 10.1021/jf990772i. [DOI] [PubMed] [Google Scholar]
  • 104.Rickert WS, Joza PJ, Sharifi M, Wu J, Lauterbach JH. Reductions in the tobacco specific nitrosamine (TSNA) content of tobaccos taken from commercial Canadian cigarettes and corresponding reductions in TSNA deliveries in mainstream smoke from such cigarettes. Regul Toxicol Pharmacol. 2008 doi: 10.1016/j.yrtph.2008.04.009. [DOI] [PubMed] [Google Scholar]
  • 105.Hoffmann D, Djordjevic M. Chemical composition and carcinogenicity of smokeless tobacco. Adv Dent Res. 1997;11:322–329. doi: 10.1177/08959374970110030301. [DOI] [PubMed] [Google Scholar]
  • 106.Pappas RS, Stanfill SB, Watson CH, Ashley DL. Analysis of toxic metals in commercial moist snuff and Alaskan iqmik. J Anal Toxicol. 2008;32:281–291. doi: 10.1093/jat/32.4.281. [DOI] [PubMed] [Google Scholar]
  • 107.Watson CH, Ashley DL. Quantitative analysis of acetates in cigarette tobacco using solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr Sci. 2000;38:137–144. doi: 10.1093/chromsci/38.4.137. [DOI] [PubMed] [Google Scholar]
  • 108.McNeill A, Bedi R, Islam S, Alkhatib MN, West R. Levels of toxins in oral tobacco products in the UK. Tob Control. 2006;15:64–67. doi: 10.1136/tc.2005.013011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Wu J, Joza P, Sharifi M, Rickert WS, Lauterbach JH. Quantitative method for the analysis of tobacco-specific nitrosamines in cigarette tobacco and mainstream cigarette smoke by use of isotope dilution liquid chromatography tandem mass spectrometry. Anal Chem. 2008;80:1341–1345. doi: 10.1021/ac702100c. [DOI] [PubMed] [Google Scholar]
  • 110.Rickert WS, Wright WG, Trivedi AH, Momin RA, Lauterbach JH. A comparative study of the mutagenicity of various types of tobacco products. Regul Toxicol Pharmacol. 2007;48:320–330. doi: 10.1016/j.yrtph.2007.05.003. [DOI] [PubMed] [Google Scholar]
  • 111.Rickert WS, Trivedi AH, Momin RA, Wright WG, Lauterbach JH. Effect of smoking conditions and methods of collection on the mutagenicity and cytotoxicity of cigarette mainstream smoke. Toxicol Sci. 2007;96:285–293. doi: 10.1093/toxsci/kfl195. [DOI] [PubMed] [Google Scholar]
  • 112.Celebucki CC, Wayne GF, Connolly GN, Pankow JF, Chang EI. Characterization of measured menthol in 48 U.S. cigarette sub-brands. Nicotine Tob Res. 2005;7:523–531. doi: 10.1080/14622200500186270. [DOI] [PubMed] [Google Scholar]
  • 113.Craver R. New Camel brand contains crushable capsule. Winston-Salem Journal. 2008 May 5; [Google Scholar]
  • 114.Associated Press. RJ Reynolds Sued Over Cigarette Ad Claims. [9-2-2008];2008 http://health.dailynewscentral.com/content/view/1368/62. Ref Type: Electronic Citation. [Google Scholar]
  • 115.Kozlowski LT. In: Some lessons from the history of American tobacco advertising and its regulations in the 20th century. Ferrence R, Slade J, Room R, Pope Me, editors. Washington, D.C.: American Public Health Association; 2000. Ref Type: Generic. [Google Scholar]
  • 116.Biener Lois, Bogen Karen, Connolly Gregory. Impact of corrective health information on consumers' perceptions of "reduced exposure" tobacco products. Tob Control. 2007;16:306–311. doi: 10.1136/tc.2006.019240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Giovino GA, Tomar SL, Reddy MN, et al. Cigarettes. Bethesda: National Institutes of Health; 1996. Attitudes, Knowledge, and Beliefs About Low-Yield Cigarettes Among Adolescents and Adults. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S; pp. 39–58. [Google Scholar]
  • 118.Hamilton WL, Norton G, Ouellette TK, Rhodes WM, Kling R, Connolly GN. Smokers' responses to advertisements for regular and light cigarettes and potential reduced-exposure tobacco products. Nicotine Tob Res. 2004;6(Suppl 3)(S353):S362. doi: 10.1080/14622200412331320752. [DOI] [PubMed] [Google Scholar]
  • 119.Shiffman S, Pillitteri JL, Burton SL, Di Marino ME. Smoker and ex-smoker reactions to cigarettes claiming reduced risk. Tob Control. 2004;13:78–84. doi: 10.1136/tc.2003.005272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Shiffman S, Jarvis MJ, Pillitteri JL, Di Marino ME, Gitchell JG, Kemper KE. UK smokers' and ex-smokers' reactions to cigarettes promising reduced risk. Addiction. 2007;102:156–160. doi: 10.1111/j.1360-0443.2006.01650.x. [DOI] [PubMed] [Google Scholar]
  • 121.Hurt RD, Robertson CR. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA. 1998;280:1173–1181. doi: 10.1001/jama.280.13.1173. [DOI] [PubMed] [Google Scholar]
  • 122.Lewis MJ, Wackowski O. Dealing with an innovative industry: a look at flavored cigarettes promoted by mainstream brands. Am J Public Health. 2006;96:244–251. doi: 10.2105/AJPH.2004.061200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Lewis MJ, Delnevo CD, Slade J. Tobacco industry direct mail marketing and participation by New Jersey adults. Am J Public Health. 2004;94:257–259. doi: 10.2105/ajph.94.2.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Lewis MJ, Yulis SG, Delnevo C, Hrywna M. Tobacco industry direct marketing after the Master Settlement Agreement. Health Promot Pract. 2004;5(3 Suppl):75S–83S. doi: 10.1177/1524839904264596. [DOI] [PubMed] [Google Scholar]
  • 125.Wakefield M, Germain D, Henriksen L. The effect of retail cigarette pack displays on impulse purchase. Addiction. 2008;103:322–328. doi: 10.1111/j.1360-0443.2007.02062.x. [DOI] [PubMed] [Google Scholar]
  • 126.Slater Sandy, Giovino Gary, Chaloupka Frank. Surveillance of tobacco industry retail marketing activities of reduced harm products. Nicotine & Tobacco Research. 2008;10:187–193. doi: 10.1080/14622200701704947. [DOI] [PubMed] [Google Scholar]
  • 127.Centers for Disease Control and Prevention (CDC) Point-of-purchase tobacco environments and variation by store type--United States, 1999. MMWR Morb Mortal Wkly Rep. 2002;51:184–187. [PubMed] [Google Scholar]
  • 128.Feighery EC, Ribisl KM, Schleicher N, Lee RE, Halvorson S. Cigarette advertising and promotional strategies in retail outlets: results of a statewide survey in California. Tob Control. 2001;10:184–188. doi: 10.1136/tc.10.2.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Slater S, Chaloupka FJ, Wakefield M. State variation in retail promotions and advertising for Marlboro cigarettes. Tob Control. 2001;10:337–339. doi: 10.1136/tc.10.4.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Feighery EC, Schleicher NC, Boley Cruz T, Unger JB. An examination of trends in amount and type of cigarette advertising and sales promotions in California stores, 2002–2005. Tob Control. 2008;17:93–98. doi: 10.1136/tc.2007.022046. [DOI] [PubMed] [Google Scholar]
  • 131.Celebucki CC, Diskin K. A longitudinal study of externally visible cigarette advertising on retail storefronts in Massachusetts before and after the Master Settlement Agreement. Tob Control. 2002;11(Suppl 2):ii47–ii53. doi: 10.1136/tc.11.suppl_2.ii47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Hrywna M, Delnevo CD, Lewis MJ. Adult recall of tobacco advertising on the Internet. Nicotine Tob Res. 2007;9:1103–1107. doi: 10.1080/14622200701488442. [DOI] [PubMed] [Google Scholar]
  • 133.Scheffels J. A difference which makes a difference: young adult smokers' accounts of cigarette brands and package design. Tob Control. 2008 doi: 10.1136/tc.2007.021592. [DOI] [PubMed] [Google Scholar]
  • 134.Wakefield M, Morley C, Horan JK, Cummings KM. The cigarette pack as image: new evidence from tobacco industry documents. Tob Control. 2002;11(Suppl 1):I73–I80. doi: 10.1136/tc.11.suppl_1.i73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Wakefield M, Letcher T. My pack is cuter than your pack. Tob Control. 2002;11:154–156. doi: 10.1136/tc.11.2.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Sandelowski MI, Voils C, Barroso J. Comparability work and the management of difference in research synthesis studies. Soc Sci Med. 2007;64:236–247. doi: 10.1016/j.socscimed.2006.08.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Nelson DE, Evans WD, Pederson LL, Babb S, London J, McKenna J. A national surveillance system for tracking tobacco news stories. Am J Prev Med. 2007;32:79–85. doi: 10.1016/j.amepre.2006.09.001. [DOI] [PubMed] [Google Scholar]
  • 138.Reed MB, Anderson CM, Burns DM. The temporal relationship between advertising and sales of low-tar cigarettes. 2006;6:441. doi: 10.1136/tc.2005.015354. 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139.Federal Trade Commission. Cigarette Report for 2004 and 2005. Washington, DC: Federal Trade Commission; 2007. Ref Type: Report. [Google Scholar]
  • 140.Ruel E, Mani N, Sandoval A, et al. After the Master Settlement Agreement: trends in the American tobacco retail environment from 1999 to 2002. Health Promot Pract. 2004;5(3 Suppl):99S–110S. doi: 10.1177/1524839904264603. [DOI] [PubMed] [Google Scholar]
  • 141.Loomis BR, Farrelly MC, Mann NH. The association of retail promotions for cigarettes with the Master Settlement Agreement, tobacco control programmes and cigarette excise taxes. Tob Control. 2006;15:458–463. doi: 10.1136/tc.2006.016378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142.Loomis BR, Farrelly MC, Nonnemaker JM, Mann NH. Point of purchase cigarette promotions before and after the Master Settlement Agreement:exploring retail scanner data. Tob Control. 2006;15:140–142. doi: 10.1136/tc.2005.011262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143.Winer RS. Experimentation in the 21st century: the importance of external validity. J Acad Mark Sci. 1999;27:349–358. [Google Scholar]
  • 144.Cummings KM, Hyland A, Bansal MA, Giovino GA. What do Marlboro Lights smokers know about low-tar cigarettes? Nicotine Tob Res. 2004;6:(Suppl 3):S323–S332. doi: 10.1080/14622200412331320725. [DOI] [PubMed] [Google Scholar]
  • 145.Hughes JR, Keely JP, Callas PW. Ever users versus never users of a "less risky" cigarette. Psychol Addict Behav. 2005;19:439–442. doi: 10.1037/0893-164X.19.4.439. [DOI] [PubMed] [Google Scholar]
  • 146.Kozlowski LT, Goldberg ME, Yost BA. Measuring smokers' perceptions of the health risks from smoking light cigarettes. Am J Public Health. 2000;90:1318–1319. doi: 10.2105/ajph.90.8.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147.Kozlowski Lynn T, Pillitteri Janine L. Beliefs about "Light" and "Ultra Light" cigarettes and efforts to change those beliefs: an overview of early efforts and published research. Tob Control. 2001;10:12–16. doi: 10.1136/tc.10.suppl_1.i12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.O'Connor RJ, Hyland A, Giovino GA, Fong GT, Cummings KM. Smoker awareness of and beliefs about supposedly less-harmful tobacco products. Am J Prev Med. 2005;29:85–90. doi: 10.1016/j.amepre.2005.04.013. [DOI] [PubMed] [Google Scholar]
  • 149.Parascandola M. Lessons from the history of tobacco harm reduction: The National Cancer Institute's Smoking and Health Program and the "less hazardous cigarette". Nicotine Tob Res. 2005;7:779–789. doi: 10.1080/14622200500262584. [DOI] [PubMed] [Google Scholar]
  • 150.Parascandola M, Hurd AL, Augustson E. Consumer awareness and attitudes related to new potential reduced-exposure tobacco products. Am J Health Behav. 2008;32:431–437. doi: 10.5555/ajhb.2008.32.4.431. [DOI] [PubMed] [Google Scholar]
  • 151.Shiffman S, Gitchell JG, Warner KE, Slade J, Henningfield JE, Pinney JM. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res. 2002;4(Suppl 2):S113–S129. doi: 10.1080/1462220021000032717. [DOI] [PubMed] [Google Scholar]
  • 153.Pederson LL, Nelson DE. Literature review and summary of perceptions, attitudes, beliefs, and marketing of potentially reduced exposure products: communication implications. Nicotine Tob Res. 2007;9:525–534. doi: 10.1080/14622200701239548. [DOI] [PubMed] [Google Scholar]
  • 154.Caraballo RS, Pederson LL, Gupta N. New tobacco products: do smokers like them? Tob Control. 2006;15:39–44. doi: 10.1136/tc.2005.012856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155.O'Hegarty M, Richter P, Pederson LL. What do adult smokers think about ads and promotional materials for PREPs? Am J Health Behav. 2007;31:526–534. doi: 10.5555/ajhb.2007.31.5.526. [DOI] [PubMed] [Google Scholar]
  • 156.Freeman B, Chapman S. Is "YouTube" telling or selling you something? Tobacco content on the YouTube video-sharing website. Tob Control. 2007;16:207–210. doi: 10.1136/tc.2007.020024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157.Moreno MA, Parks M, Richardson LP. What are adolescents showing the world about their health risk behaviors on MySpace? MedGenMed. 2007;9:9. [PMC free article] [PubMed] [Google Scholar]
  • 158.Freeman B, Chapman S. Gone viral? Heard the buzz? A guide for public health practitioners and researchers on how Web 2.0 can subvert advertising restrictions and spread health information. J Epidemiol Community Health. 2008;62:778–782. doi: 10.1136/jech.2008.073759. [DOI] [PubMed] [Google Scholar]
  • 159.Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006;83(Suppl 1):S31–S39. doi: 10.1016/j.drugalcdep.2005.11.027. [DOI] [PubMed] [Google Scholar]
  • 160.Rayport J. The Virus of Marketing. Fast Company [6] 1996 Ref Type: Magazine Article. [Google Scholar]
  • 161.Richter P, Pechacek T, Swahn M, Wagman V. Reducing levels of toxic chemicals in cigarette smoke: a new Healthy People 2010 objective. Public Health Rep. 2008;123:30–38. doi: 10.1177/003335490812300105. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES